• Search
  • Advanced Search

Review

October 19, 2021


Crosstalk between tumor-associated macrophages and neighboring cells in hepatocellular carcinoma
Pil Soo Sung
Clin Mol Hepatol. 2022;28(3):333-350.

The tumor microenvironment generally shows a substantial immunosuppressive activity in hepatocellular carcinoma (HCC), accounting for the suboptimal efficacy of immune-based treatments for this difficult-to-treat cancer. The crosstalk between tumor cells...

Review

November 26, 2021


The best predictive model for hepatocellular carcinoma in patients with chronic hepatitis B infection
Jung Hwan Yu, Soon Gu Cho, Young-Joo Jin, et al.
Clin Mol Hepatol. 2022;28(3):351-361.

Chronic hepatitis B (CHB) seriously threatens human health. About 820,000 deaths annually are due to related complications such as hepatitis B and hepatocellular carcinoma (HCC). Recently, the use of oral...

Review

December 27, 2021


Imaging diagnosis of hepatocellular carcinoma: Future directions with special emphasis on hepatobiliary magnetic resonance imaging and contrast-enhanced ultrasound
Junghoan Park, Jeong Min Lee, Tae-Hyung Kim, et al.
Clin Mol Hepatol. 2022;28(3):362-379.

Hepatocellular carcinoma (HCC) is a unique cancer entity that can be noninvasively diagnosed using imaging modalities without pathologic confirmation. In 2018, several major guidelines for HCC were updated to include...

Review

January 13, 2022


Statin and aspirin for chemoprevention of hepatocellular carcinoma: Time to use or wait further?
Myung Ji Goh, Dong Hyun Sinn
Clin Mol Hepatol. 2022;28(3):380-395.
Preclinical studies highlighted potential therapeutic applications of aspirin and statins as anticancer agents based on their pleiotropic effects. Epidemiologic studies suggested the role of aspirin and statins in the chemoprevention...

Review

January 14, 2022


Intrahepatic cholangiocarcinoma: Tumour heterogeneity and its clinical relevance
Mina Komuta
Clin Mol Hepatol. 2022;28(3):396-407.

Treatment of intrahepatic cholangiocarcinoma (iCCA) is currently at a significant turning point due to the identification of isocitrate dehydrogenase (IDH) mutations and fibroblast growth factor receptor (FGFR) fusions that can...

Review

February 17, 2022


RNA interference as a novel treatment strategy for chronic hepatitis B infection
Rex Wan-Hin Hui, Lung-Yi Mak, Wai-Kay Seto, et al.
Clin Mol Hepatol. 2022;28(3):408-424.

Chronic hepatitis B (CHB) is a major cause of liver-related morbidity and mortality. Functional cure of CHB, defined as sustainable hepatitis B surface antigen (HBsAg) seroclearance, is associated with improved...

Review

July 1, 2022


Therapeutic mechanisms and beneficial effects of non-antidiabetic drugs in chronic liver diseases
Han Ah Lee, Young Chang, Pil Soo Sung, et al.
Clin Mol Hepatol. 2022;28(3):425-472.

The global burden of chronic liver disease (CLD) is substantial. Due to the limited indication of and accessibility to antiviral therapy in viral hepatitis and lack of effective pharmacological treatment...

Original Article

March 2, 2022


Non-alcoholic fatty liver disease increases risk of carotid atherosclerosis and ischemic stroke: An updated meta-analysis with 135,602 individuals
Ansel Shao Pin Tang, Kai En Chan, Jingxuan Quek, et al.
Clin Mol Hepatol. 2022;28(3):483-496.

Background/Aims: Non-alcoholic fatty liver disease (NAFLD) is associated with the development of cardiovascular disease. While existing studies have examined cardiac remodeling in NAFLD, there has been less emphasis on the...

Original Article

April 28, 2022


Discovery of dipeptidyl peptidase-4 inhibitor specific biomarker in non-alcoholic fatty liver disease mouse models using modified basket trial
Ju Hee Oh, Dae Won Jun, Hye Young Kim, et al.
Clin Mol Hepatol. 2022;28(3):497-509.

Background/Aims: We aimed to define an optimal target population and drug-specific biomarkers that may predict dipeptidyl peptidase (DPP)-4 inhibitor responses in non-alcoholic fatty liver disease (NAFLD). Methods: An exploration study (study...

Original Article

March 17, 2022


Association of non-alcoholic fatty liver disease with incident dementia later in life among elder adults
Seogsong Jeong, Yun Hwan Oh, Seulggie Choi, et al.
Clin Mol Hepatol. 2022;28(3):510-521.

Background/Aims: Accumulating evidence suggests a link between non-alcoholic fatty liver disease (NAFLD) and brain health. However, population-based evidence on the association between NAFLD and dementia remains unclear. This study was...

Original Article

May 4, 2022


Gut-derived lipopolysaccharide promotes alcoholic hepatosteatosis and subsequent hepatocellular carcinoma by stimulating neutrophil extracellular traps through toll-like receptor 4
Yang Liu, Xin Zhang, Shuo Chen, et al.
Clin Mol Hepatol. 2022;28(3):522-539.

Background/Aims: Binge drinking leads to many disorders, including alcoholic hepatosteatosis, which is characterized by intrahepatic neutrophil infiltration and increases the risk of hepatocellular carcinoma (HCC). Molecular mechanisms may involve the...

Original Article

May 6, 2022


Reappraisal of sepsis-3 and CLIF-SOFA as predictors of mortality in patients with cirrhosis and infection presenting to the emergency department: A multicenter study
Ji Hyun Kim, Baek Gyu Jun, Minjong Lee, et al.
Clin Mol Hepatol. 2022;28(3):540-552.

Background/Aims: Sepsis-3 criteria and quick Sequential Organ Failure Assessment (qSOFA) have been advocated to be used in defining sepsis in the general population. We aimed to compare the Sepsis-3 criteria...

Original Article

May 11, 2022


Effect of moderate-to-severe hepatic steatosis on neutralising antibody response among BNT162b2 and CoronaVac recipients
Ka Shing Cheung, Lok Ka Lam, Rex Wan Hin Hui, et al.
Clin Mol Hepatol. 2022;28(3):553-564.

Background/Aims: Studies of hepatic steatosis (HS) effect on COVID-19 vaccine immunogenicity are lacking. We aimed to compare immunogenicity of BNT162b2 and CoronaVac among moderate/severe HS and control subjects. Methods: Two hundred...

Original Article

May 19, 2022


The effect of diabetes and prediabetes on the prevalence, complications and mortality in nonalcoholic fatty liver disease
Cheng Han Ng, Kai En Chan, Yip Han Chin, et al.
Clin Mol Hepatol. 2022;28(3):565-574.

Background/Aims: Nonalcoholic fatty liver disease (NAFLD) is closely associated with diabetes. The cumulative impact of both diseases synergistically increases risk of adverse events. However, present population analysis is predominantly conducted...
Current Issue
Volume 28(3); Jul 2022
Review
1640
Crosstalk between tumor-associated macrophages and neighboring cells in hepatocellular carcinoma
Pil Soo Sung
Clin Mol Hepatol. 2022;28(3):333-350.   Published online October 19, 2021
View: 12442   Download: 244  Citations: 3
1647
The best predictive model for hepatocellular carcinoma in patients with chronic hepatitis B infection
Jung Hwan Yu, Soon Gu Cho, Young-Joo Jin, Jin-Woo Lee
Clin Mol Hepatol. 2022;28(3):351-361.   Published online November 26, 2021
View: 1920   Download: 152
1651
Imaging diagnosis of hepatocellular carcinoma: Future directions with special emphasis on hepatobiliary magnetic resonance imaging and contrast-enhanced ultrasound
Junghoan Park, Jeong Min Lee, Tae-Hyung Kim, Jeong Hee Yoon
Clin Mol Hepatol. 2022;28(3):362-379.   Published online December 27, 2021
View: 1748   Download: 141
Statin and aspirin for chemoprevention of hepatocellular carcinoma: Time to use or wait further?
Myung Ji Goh, Dong Hyun Sinn
Clin Mol Hepatol. 2022;28(3):380-395.   Published online January 13, 2022
View: 1587   Download: 98
1658
Intrahepatic cholangiocarcinoma: Tumour heterogeneity and its clinical relevance
Mina Komuta
Clin Mol Hepatol. 2022;28(3):396-407.   Published online January 14, 2022
View: 1932   Download: 222  Citation: 1
1664
RNA interference as a novel treatment strategy for chronic hepatitis B infection
Rex Wan-Hin Hui, Lung-Yi Mak, Wai-Kay Seto, Man-Fung Yuen
Clin Mol Hepatol. 2022;28(3):408-424.   Published online February 17, 2022
View: 2246   Download: 335  Citations: 3
1692
Therapeutic mechanisms and beneficial effects of non-antidiabetic drugs in chronic liver diseases
Han Ah Lee, Young Chang, Pil Soo Sung, Eileen L. Yoon, Hye Won Lee, Jeong-Ju Yoo, Young-Sun Lee, Jihyun An, Do Seon Song, Young Youn Cho, Seung Up Kim, Yoon Jun Kim
Clin Mol Hepatol. 2022;28(3):425-472.   Published online July 1, 2022
View: 1864   Download: 142
Editorial
1687
Does nonalcoholic fatty liver disease predispose patients to carotid arteriosclerosis and ischemic stroke?
Qian Jin, Rui-Xu Yang, Jian-Gao Fan
Clin Mol Hepatol. 2022;28(3):473-477.   Published online June 22, 2022
View: 864   Download: 51
A crystal ball to forecast treatment responsiveness in nonalcoholic fatty liver disease
Seonghwan Hwang, Won Kim
Clin Mol Hepatol. 2022;28(3):478-480.   Published online June 16, 2022
View: 857   Download: 39
Association of nonalcoholic fatty liver disease with incident dementia later in life among elderly adults
Byoung Seok Ye
Clin Mol Hepatol. 2022;28(3):481-482.   Published online May 16, 2022
View: 834   Download: 41
Original Article
1667
Non-alcoholic fatty liver disease increases risk of carotid atherosclerosis and ischemic stroke: An updated meta-analysis with 135,602 individuals
Ansel Shao Pin Tang, Kai En Chan, Jingxuan Quek, Jieling Xiao, Phoebe Tay, Margaret Teng, Keng Siang Lee, Snow Yunni Lin, May Zin Myint, Benjamin Tan, Vijay K Sharma, Darren Jun Hao Tan, Wen Hui Lim, Apichat Kaewdech, Daniel Huang, Nicholas WS Chew, Mohammad Shadab Siddiqui, Arun J Sanyal, Mark Muthiah, Cheng Han Ng
Clin Mol Hepatol. 2022;28(3):483-496.   Published online March 2, 2022
View: 2265   Download: 155  Citations: 7
1675
Discovery of dipeptidyl peptidase-4 inhibitor specific biomarker in non-alcoholic fatty liver disease mouse models using modified basket trial
Ju Hee Oh, Dae Won Jun, Hye Young Kim, Seung Min Lee, Eileen L. Yoon, Jungwook Hwang, Jung Hwan Park, Hanbi Lee, Wankyu Kim, Hyunsung Kim
Clin Mol Hepatol. 2022;28(3):497-509.   Published online April 28, 2022
View: 1342   Download: 88
1669
Association of non-alcoholic fatty liver disease with incident dementia later in life among elder adults
Seogsong Jeong, Yun Hwan Oh, Seulggie Choi, Jooyoung Chang, Sung Min Kim, Joung Sik Son, Gyeongsil Lee, Joseph C Ahn, Dong Hyeon Lee, Bo Kyung Koo, Won Kim, Sang Min Park
Clin Mol Hepatol. 2022;28(3):510-521.   Published online March 17, 2022
View: 1803   Download: 169  Citations: 2
1676
Gut-derived lipopolysaccharide promotes alcoholic hepatosteatosis and subsequent hepatocellular carcinoma by stimulating neutrophil extracellular traps through toll-like receptor 4
Yang Liu, Xin Zhang, Shuo Chen, Jiazhong Wang, Shuo Yu, Yiming Li, Meng Xu, Harouna Aboubacar, Junhui Li, Tao Shan, Jixin Wang, Gang Cao
Clin Mol Hepatol. 2022;28(3):522-539.   Published online May 4, 2022
View: 1356   Download: 90  Citation: 1
1677
Reappraisal of sepsis-3 and CLIF-SOFA as predictors of mortality in patients with cirrhosis and infection presenting to the emergency department: A multicenter study
Ji Hyun Kim, Baek Gyu Jun, Minjong Lee, Hye Ah Lee, Tae Suk Kim, Jeong Won Heo, Da Hye Moon, Seong Hee Kang, Ki Tae Suk, Moon Young Kim, Young Don Kim, Gab Jin Cheon, Soon Koo Baik, Dong Joon Kim, Dae Hee Choi
Clin Mol Hepatol. 2022;28(3):540-552.   Published online May 6, 2022
View: 1053   Download: 54
1679
Effect of moderate-to-severe hepatic steatosis on neutralising antibody response among BNT162b2 and CoronaVac recipients
Ka Shing Cheung, Lok Ka Lam, Rex Wan Hin Hui, Xianhua Mao, Ruiqi R Zhang, Kwok Hung Chan, Ivan FN Hung, Wai Kay Seto, Man-Fung Yuen
Clin Mol Hepatol. 2022;28(3):553-564.   Published online May 11, 2022
View: 1071   Download: 62
1681
The effect of diabetes and prediabetes on the prevalence, complications and mortality in nonalcoholic fatty liver disease
Cheng Han Ng, Kai En Chan, Yip Han Chin, Rebecca Wenling Zeng, Pei Chen Tsai, Wen Hui Lim, Darren Jun Hao Tan, Chin Meng Khoo, Lay Hoon Goh, Zheng Jye Ling, Anand Kulkarni, Lung-Yi Loey Mak, Daniel Q Huang, Mark Chan, Nicholas WS Chew, Mohammad Shadab Siddiqui, Arun J. Sanyal, Mark Muthiah
Clin Mol Hepatol. 2022;28(3):565-574.   Published online May 19, 2022
View: 1775   Download: 114  Citations: 3
Letter to the Editor
1672
Clinical significance of the discrepancy between radiological findings and biochemical responses in atezolizumab plus bevacizumab for hepatocellular carcinoma
Hideki Iwamoto, Shigeo Shimose, Takashi Niizeki, Hironori Koga, Takuji Torimura
Clin Mol Hepatol. 2022;28(3):575-579.   Published online April 21, 2022
View: 1042   Download: 152
Snapshot
1693
Microbiome and metabolomics in alcoholic liver disease
Raja Ganesan, Ki Tae Suk
Clin Mol Hepatol. 2022;28(3):580-582.   Published online July 1, 2022
View: 1098   Download: 53  Citation: 1

Clinical and
Molecular
Hepatology

Print ISSN: 2287-2728
Online ISSN: 2287-285X

  • PubMed Central
  • PubMed
  • Scopus
  • KoreaMed
  • KoMCI
  • ScienceCentral
  • DOAJ
  • GoogleScholar
  • Similarity Check
  • Crossref Cited-by Linking
  • CrossMark
  • Funder Registry
  • Metadata
  • ORCID
  • MeSH on Demand
  • COPE
  • EMBASE
  • KOFST
  • ICMJE
  • Web of SCIENCE
ABOUT
BROWSE ARTICLES
CURRENT ISSUE
FOR CONTRIBUTORS
Editorial Office
The Korean Association for the Study of the Liver
Room A1210, 53 Mapo-daero(MapoTrapalace, Dowha-dong), Mapo-gu, Seoul, 04158, Korea
TEL: +82-2-703-0051   FAX: +82-2-703-0071    E-mail: kasl@kams.or.kr
Copyright © The Korean Association for the Study of the Liver.         
COUNTER
TODAY : 335
TOTAL : 973701
Close layer